Market Overview

FDA Approves Genzyme's AUBAGIO Oral Treatment for Relapsing Multiple Sclerosis

Genzyme,
a Sanofi company (NYSE: SNY), announced today
that the U.S. Food and Drug Administration (FDA) has approved AUBAGIO®
(teriflunomide) as a new once-daily, oral treatment indicated for
patients with relapsing forms of multiple sclerosis (MS). AUBAGIO has
shown significant efficacy across key measures of MS disease activity,
including reducing relapses, slowing the progression of physical
disability, and reducing the number of brain lesions as detected by MRI.

AUBAGIO (R) 14mg

“We are very excited to introduce AUBAGIO as a new treatment option
that can make a difference in the lives of people with multiple
sclerosis,” said David Meeker, President and CEO, Genzyme. “The
approval of

See full press release

Posted-In: News Contracts Global

 

Related Articles (SNY)

Around the Web, We're Loving...

Get Benzinga's Newsletters